DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
暂无分享,去创建一个
Juan F. García | N. Malats | F. Real | J. Maroto | A. Prat | A. Font | I. Durán | D. Castellano | M. Álvarez-Maestro | E. Grande | O. Reig | P. Galván | Á. Pinto | J. Puente | X. G. Muro | J. Burgos | I. Galante | T. A. Gordoa | Félix Guerrero | M. Dominguez | Xavier Garcia del Muro | J. P. Maroto | M. Domínguez